Krystal Biotech, Inc.
KRYSKrystal Biotech is a commercial-stage biotechnology company specializing in the development and commercialization of genetic medicines for rare and serious diseases.
Earnings
Next report
Aug 3, 2026 (In 5 days)Valuation & ratios
Segments
By geography
Competitors
By market cap
By revenue growth
By net margin
Profile
Krystal Biotech is a commercial-stage biotechnology company specializing in the development and commercialization of genetic medicines for rare and serious diseases. The company utilizes a proprietary gene therapy platform based on engineered herpes simplex virus-1 (HSV-1) to deliver therapeutic transgenes through non-invasive or minimally invasive administration. Their integrated model encompasses discovery, clinical development, and in-house commercial-scale CGMP manufacturing.
Krystal Biotech is a leader in redosable gene therapy with the first-ever FDA-approved topical gene therapy and maintains a competitive advantage through vertically integrated manufacturing.
Questions, answered.
- What is Krystal Biotech, Inc.'s market cap?
- Krystal Biotech, Inc. (KRYS) has a market capitalization of $10.4B and trades on NASDAQ.
- What is Krystal Biotech, Inc.'s revenue and profitability?
- Krystal Biotech, Inc. generated $417.3M in trailing twelve-month revenue with net income of $225.0M, representing a net margin of 53.9%, with free cash flow of $237.4M. These figures are based on the Q1 2026 filing.
- Who are Krystal Biotech, Inc.'s competitors?
- Krystal Biotech, Inc.'s key competitors include Abeona Therapeutics, Sarepta Therapeutics, Soligenix, Inc. Common Stock, and others. These companies compete in similar markets and product categories.
- What subsidiaries does Krystal Biotech, Inc. have?
- Krystal Biotech, Inc.'s subsidiaries include Jeune Aesthetics, Inc..
- Where is Krystal Biotech, Inc. headquartered?
- Krystal Biotech, Inc. is headquartered in United States of America and employs approximately 229 people. It has been publicly traded since 2017.
